Kovack Advisors Inc. Has $224,000 Position in AstraZeneca PLC (NASDAQ:AZN)

Kovack Advisors Inc. lessened its holdings in shares of AstraZeneca PLC (NASDAQ:AZN) by 6.2% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 2,871 shares of the company’s stock after selling 189 shares during the quarter. Kovack Advisors Inc.’s holdings in AstraZeneca were worth $224,000 as of its most recent SEC filing.

Several other institutional investors have also recently bought and sold shares of AZN. McClarren Financial Advisors Inc. increased its position in shares of AstraZeneca by 320.8% during the third quarter. McClarren Financial Advisors Inc. now owns 324 shares of the company’s stock worth $25,000 after acquiring an additional 247 shares in the last quarter. GHP Investment Advisors Inc. bought a new stake in AstraZeneca during the 2nd quarter worth approximately $26,000. Capital Performance Advisors LLP purchased a new stake in shares of AstraZeneca in the third quarter worth approximately $28,000. Pathway Financial Advisers LLC bought a new position in shares of AstraZeneca in the first quarter valued at approximately $29,000. Finally, Hobbs Group Advisors LLC bought a new position in shares of AstraZeneca in the second quarter valued at approximately $35,000. Institutional investors and hedge funds own 20.35% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms recently commented on AZN. TD Cowen increased their price target on AstraZeneca from $90.00 to $95.00 and gave the company a “buy” rating in a research report on Monday, August 12th. Erste Group Bank upgraded shares of AstraZeneca from a “hold” rating to a “buy” rating in a research note on Wednesday, September 11th. Finally, Deutsche Bank Aktiengesellschaft raised shares of AstraZeneca from a “sell” rating to a “hold” rating in a research report on Wednesday, November 6th. Two research analysts have rated the stock with a hold rating, seven have assigned a buy rating and two have given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus target price of $89.75.

AstraZeneca Trading Down 2.8 %

NASDAQ AZN opened at $63.23 on Friday. The stock has a market capitalization of $196.05 billion, a price-to-earnings ratio of 30.25, a PEG ratio of 1.20 and a beta of 0.47. The business’s fifty day moving average is $75.03 and its 200-day moving average is $78.20. The company has a debt-to-equity ratio of 0.71, a current ratio of 0.93 and a quick ratio of 0.69. AstraZeneca PLC has a one year low of $60.47 and a one year high of $87.68.

AstraZeneca (NASDAQ:AZN) last released its earnings results on Tuesday, November 12th. The company reported $1.04 earnings per share for the quarter, beating analysts’ consensus estimates of $1.01 by $0.03. AstraZeneca had a net margin of 12.68% and a return on equity of 30.01%. The firm had revenue of $13.57 billion for the quarter, compared to analysts’ expectations of $13.08 billion. During the same period in the previous year, the company earned $0.87 earnings per share. The company’s quarterly revenue was up 18.0% on a year-over-year basis. Equities research analysts predict that AstraZeneca PLC will post 4.07 EPS for the current year.

AstraZeneca Company Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.